{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:18:19Z","timestamp":1783383499428,"version":"3.54.6"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T00:00:00Z","timestamp":1725494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nutr."],"abstract":"<jats:sec><jats:title>Background and aims<\/jats:title><jats:p>Vonoprazan, a novel acid suppressant, has been employed in the treatment of peptic ulcer disease in recent years. However, the efficacy and safety of vonoprazan versus proton-pump inhibitors remains controversial. To address this gap, a systematic review and network meta-analysis were conducted to evaluate the efficacy and safety of vonoprazan in comparison with various proton-pump inhibitors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Randomized controlled trials that met selection criteria in PubMed (Medline), EMBASE and the Cochrane Library were searched up to July 15, 2024. The primary outcome was ulcer healing rate. Secondary outcomes were treatment-emergent adverse events and drug-related adverse events. Effect size on outcomes is presented as odds ratios with 95% confidence intervals.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Thirty-five randomized controlled trials containing 9,544 participants were included. In terms of the healing rate at 2\u2009weeks, lansoprazole 30\u2009mg ranked first, followed by vonoprazan 20\u2009mg and ilaprazole 10\u2009mg. In terms of the healing rate at 4\u2009weeks, pantoprazole 40\u2009mg ranked first, with rabeprazole 10\u2009mg and lansoprazole 30\u2009mg ranking second and third, respectively. Regarding the healing rate at 8\u2009weeks, lansoprazole 30\u2009mg is demonstrated to be the most efficacious regimen. Moreover, subgroup analysis indicated that lansoprazole 30\u2009mg is the optimal regimen in the treatment of artificial gastric ulcer at 4 and 8\u2009weeks. Importantly, lansoprazole 30\u2009mg has fewer adverse reactions and higher safety.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The optimal regimen for the treatment of peptic ulcer disease may be lansoprazole 30\u2009mg at 2 and 8\u2009weeks, while pantoprazole 40\u2009mg has demonstrated superior performance at the 4-week when compared to vonoprazan 20\u2009mg. Furthermore, lansoprazole 30\u2009mg has shown to be superior in terms of safety outcomes. These findings, derived from a network meta-analysis, necessitate further research for validation.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fnut.2024.1436993","type":"journal-article","created":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T15:27:01Z","timestamp":1725550021000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy and safety of vonoprazan versus proton pump inhibitors in the treatment of peptic ulcer disease: a systematic review and network meta-analysis for randomized controlled trails"],"prefix":"10.3389","volume":"11","author":[{"given":"Lidi","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feili","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runjie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youping","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,5]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"l5495","DOI":"10.1136\/bmj.l5495","article-title":"Peptic ulcer disease","volume":"367","author":"Sverd\u00e9n","year":"2019","journal-title":"BMJ"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0140-6736(16)32404-7","article-title":"Peptic ulcer disease","volume":"390","author":"Lanas","year":"2017","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1136\/gut.36.6.819","article-title":"Prevalence and incidence of peptic ulcer disease in a Danish county--a prospective cohort study","volume":"36","author":"Rosenstock","year":"1995","journal-title":"Gut"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1093\/ije\/dyac033","article-title":"The global burden of peptic ulcer disease in 204 countries and territories from 1990 to 2019: a systematic analysis for the global burden of disease study 2019","volume":"51","author":"Ren","year":"2022","journal-title":"Int J Epidemiol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"e854","DOI":"10.7759\/cureus.854","article-title":"Seasonal variations and trends in hospitalization for peptic ulcer disease in the United States: a 12-year analysis of the Nationwide inpatient sample","volume":"8","author":"Kanotra","year":"2016","journal-title":"Cureus"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00535-021-01769-0","article-title":"Evidence-based clinical practice guidelines for peptic ulcer disease 2020","volume":"56","author":"Kamada","year":"2021","journal-title":"J Gastroenterol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.3390\/pharmaceutics14102043","article-title":"Formulation of dosage forms with proton pump inhibitors: state of the art, challenges and future perspectives","volume":"14","author":"Srebro","year":"2022","journal-title":"Pharmaceutics"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.5009\/gnl15502","article-title":"25 years of proton pump inhibitors: a comprehensive review","volume":"11","author":"Strand","year":"2017","journal-title":"Gut Liver"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"104606","DOI":"10.1016\/j.phrs.2019.104606","article-title":"Effects of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of proton pump inhibitors","volume":"152","author":"Zhang","year":"2020","journal-title":"Pharmacol Res"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/S2468-1253(18)30037-2","article-title":"Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials","volume":"3","author":"Scally","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1111\/apt.16295","article-title":"Review article: potassium-competitive acid blockers for the treatment of acid-related disorders","volume":"53","author":"Abdel-Aziz","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"63","DOI":"10.4292\/wjgpt.v9.i7.63","article-title":"Potassium-competitive acid blockers \u2013 are they the next generation of proton pump inhibitors?","volume":"9","author":"Rawla","year":"2018","journal-title":"World J Gastrointest Pharmacol Ther"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"6","DOI":"10.5056\/jnm18139","article-title":"Role of acid suppression in acid-related diseases: proton pump inhibitor and potassium-competitive acid blocker","volume":"25","author":"Mori","year":"2019","journal-title":"J Neurogastroenterol Motil"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/apt.13876","article-title":"Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers \u2013 results from two phase 3, non-inferiority randomised controlled trials","volume":"45","author":"Miwa","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1111\/den.12857","article-title":"Effect of vonoprazan on the treatment of artificial gastric ulcers after endoscopic submucosal dissection: prospective randomized controlled trial","volume":"29","author":"Tsuchiya","year":"2017","journal-title":"Dig Endosc"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s12876-021-01822-5","article-title":"Vonoprazan versus lansoprazole in the treatment of artificial gastric ulcers after endoscopic submucossal dissection: a randomized, open-label trial","volume":"21","author":"Kawai","year":"2021","journal-title":"BMC Gastroenterol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1111\/jgh.15837","article-title":"Vonoprazan non-inferior to lansoprazole in treating duodenal ulcer and eradicating Helicobacter pylori in Asian patients","volume":"37","author":"Hou","year":"2022","journal-title":"J Gastroenterol Hepatol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1007\/s10620-018-4948-0","article-title":"Comparison of the effects of Vonoprazan and lansoprazole for treating endoscopic submucosal dissection-induced artificial ulcers","volume":"63","author":"Hirai","year":"2018","journal-title":"Dig Dis Sci"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1615092","DOI":"10.1155\/2018\/1615092","article-title":"Effects of Vonoprazan compared with esomeprazole on the healing of artificial Postendoscopic submucosal dissection ulcers: a prospective, multicenter, two-arm, randomized controlled trial","volume":"2018","author":"Ishii","year":"2018","journal-title":"Gastroenterol Res Pract"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2169\/internalmedicine.1146-18","article-title":"Randomized controlled trial comparing the effects of Vonoprazan plus Rebamipide and esomeprazole plus Rebamipide on gastric ulcer healing induced by endoscopic submucosal dissection","volume":"58","author":"Ichida","year":"2019","journal-title":"Intern Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1177\/0300060519828514","article-title":"A prospective randomized trial of a potassium competitive acid blocker vs proton pump inhibitors on the effect of ulcer healing after endoscopic submucosal dissection of gastric neoplasia","volume":"47","author":"Komori","year":"2019","journal-title":"J Int Med Res"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3164\/jcbn.20-143","article-title":"Vonoprazan vs lansoprazole for the treatment of artificial gastric ulcer after endoscopic submucosal dissection: a prospective randomized comparative study","volume":"68","author":"Ban","year":"2021","journal-title":"J Clin Biochem Nutr"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"e2017047","DOI":"10.4178\/epih.e2017047","article-title":"Network meta-analysis: application and practice using Stata","volume":"27","author":"Shim","year":"2017","journal-title":"Epidemiol Health"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13643-017-0473-z","article-title":"Approaches to interpreting and choosing the best treatments in network meta-analyses","volume":"6","author":"Mbuagbaw","year":"2017","journal-title":"Syst Rev"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/BF01537225","article-title":"Omeprazole versus placebo in duodenal ulcer healing. The United States experience","volume":"35","author":"Graham","year":"1990","journal-title":"Dig Dis Sci"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/j.1365-2036.1995.tb00415.x","article-title":"A comparison of three doses of lansoprazole (15, 30 and 60 mg) and placebo in the treatment of duodenal ulcer. The lansoprazole study group","volume":"9","author":"Avner","year":"1995","journal-title":"Aliment Pharmacol Ther"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/j.1440-1746.1995.tb01352.x","article-title":"Comparison of lansoprazole and omeprazole in the short-term management of duodenal ulcers in Taiwan","volume":"10","author":"Chang","year":"1995","journal-title":"J Gastronterol Hepatol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3109\/00365529509093265","article-title":"Lansoprazole versus omeprazole in active duodenal ulcer. A double-blind, randomized, comparative study","volume":"30","author":"Ekstr\u00f6m","year":"1995","journal-title":"Scand J Gastroenterol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1365-2036.1995.tb00346.x","article-title":"Pantoprazole versus omeprazole in the treatment of acute gastric ulcers","volume":"9","author":"Witzel","year":"1995","journal-title":"Aliment Pharmacol Ther"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/j.1365-2036.1995.tb00399.x","article-title":"Comparison of pantoprazole versus omeprazole in the treatment of acute duodenal ulceration--a multicenter study","volume":"9","author":"Rehner","year":"1995","journal-title":"Aliment Pharmacol Ther"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/j.1440-1746.1995.tb01055.x","article-title":"Prevention of duodenal ulcer relapse with omeprazole 20 mg daily: a randomized double-blind, placebo-controlled study","volume":"10","author":"Goh","year":"1995","journal-title":"J Gastroenterol Hepatol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1023\/a:1018818115047","article-title":"Double-blind comparison of lansoprazole 15 mg, lansoprazole 30 mg, and placebo in the maintenance of healed gastric ulcer","volume":"43","author":"Campbell","year":"1998","journal-title":"Dig Dis Sci"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1046\/j.1365-2036.1998.00373.x","article-title":"Comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of active gastric ulcer--a European multicentre study. The European Rabeprazole study group","volume":"12","author":"Dekkers","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/s0149-2918(99)80033-2","article-title":"Lansoprazole versus omeprazole for duodenal ulcer healing and prevention of relapse: a randomized, multicenter, double-masked trial","volume":"21","author":"Dobrilla","year":"1999","journal-title":"Clin Ther"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1046\/j.1365-2036.1999.00449.x","article-title":"Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study","volume":"13","author":"Dekkers","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/s1590-8658(00)80821-x","article-title":"Efficacy of pantoprazole in the prevention of peptic ulcer, induced by non-steroidal anti-inflammatory drugs: a prospective, placebo-controlled, double-blind, parallel-group study","volume":"32","author":"Bianchi Porro","year":"2000","journal-title":"Dig Liver Dis"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1007\/s10620-005-2907-z","article-title":"A comparative study on endoscopic ulcer healing of omeprazole versus rabeprazole with respect to CYP2C19 genotypic differences","volume":"50","author":"Ando","year":"2005","journal-title":"Dig Dis Sci"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1111\/j.1440-1746.2006.04314.x","article-title":"Comparison of the efficacy of rabeprazole 10 mg and omeprazole 20 mg for the healing rapidity of peptic ulcer diseases","volume":"21","author":"Ji","year":"2006","journal-title":"J Gastroenterol Hepatol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s00535-009-0072-4","article-title":"Randomized, parallel, double-blind comparison of the ulcer-healing effects of ilaprazole and omeprazole in the treatment of gastric and duodenal ulcers","volume":"44","author":"Ho","year":"2009","journal-title":"J Gastroenterol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1097\/MCG.0b013e3181e88515","article-title":"A new PPI, ilaprazole compared with omeprazole in the treatment of duodenal ulcer: a randomized double-blind multicenter trial","volume":"45","author":"Wang","year":"2011","journal-title":"J Clin Gastroenterol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/j.1365-2036.2012.05133.x","article-title":"Esomeprazole NSAID preventive study group. Randomised clinical trial: esomeprazole for the prevention of nonsteroidal anti-inflammatory drug-related peptic ulcers in Japanese patients","volume":"36","author":"Sugano","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1185\/03007995.2011.639353","article-title":"Ilaprazole for the treatment of duodenal ulcer: a randomized, double-blind and controlled phase III trial","volume":"28","author":"Wang","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1136\/hrt.2010.217547","article-title":"Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON)","volume":"97","author":"Scheiman","year":"2011","journal-title":"Heart"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1136\/gutjnl-2013-304722","article-title":"Multinational, double-blind, randomised, placebo-controlled, prospective study of esomeprazole in the prevention of recurrent peptic ulcer in low-dose acetylsalicylic acid users: the LAVENDER study","volume":"63","author":"Sugano","year":"2014","journal-title":"Gut"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"716","DOI":"10.4253\/wjge.v8.i19.716","article-title":"Vonoprazan 20 mg vs lansoprazole 30 mg for endoscopic submucosal dissection-induced gastric ulcers","volume":"8","author":"Takahashi","year":"2016","journal-title":"World J Gastrointest Endosc"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1136\/gutjnl-2017-314010","article-title":"Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study","volume":"67","author":"Mizokami","year":"2018","journal-title":"Gut"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1136\/gutjnl-2017-314852","article-title":"Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study","volume":"67","author":"Kawai","year":"2018","journal-title":"Gut"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1007\/s00464-018-6412-9","article-title":"Effect of ilaprazole on the healing of endoscopic submucosal dissection-induced gastric ulcer: randomized-controlled, multicenter study","volume":"33","author":"Bang","year":"2019","journal-title":"Surg Endosc"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1097\/MCG.0000000000001186","article-title":"Ilaprazole compared with rabeprazole in the treatment of duodenal ulcer: a randomized, double-blind, active-controlled, multicenter study","volume":"53","author":"Fan","year":"2019","journal-title":"J Clin Gastroenterol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s00535-018-1487-6","article-title":"Efficacy of vonoprazan in prevention of bleeding from endoscopic submucosal dissection-induced gastric ulcers: a prospective randomized phase II study","volume":"54","author":"Hamada","year":"2019","journal-title":"J Gastroenterol"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3109\/00365529409105369","article-title":"Appropriate acid suppression for optimal healing of duodenal ulcer and gastro-oesophageal reflux disease","volume":"201","author":"Howden","year":"1994","journal-title":"Scand J Gastroenterol Suppl"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1053\/j.gastro.2008.05.021","article-title":"Control of gastric acid secretion in health and disease","volume":"134","author":"Schubert","year":"2008","journal-title":"Gastroenterology"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/apt.17510","article-title":"A translational pharmacokinetic\/pharmacodynamic approach supports optimal vonoprazan dosing for erosive oesophagitis and Helicobacter pylori infection","volume":"58","author":"Scarpignato","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s40262-015-0326-7","article-title":"The first-in-class potassium-competitive acid blocker, vonoprazan fumarate: pharmacokinetic and pharmacodynamic considerations","volume":"55","author":"Echizen","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1111\/apt.13325","article-title":"Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects\u2014a randomised open-label cross-over study","volume":"42","author":"Sakurai","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.3390\/ph17060698","article-title":"Comparative efficacy and safety of potassium-competitive acid blockers vs. proton pump inhibitors for peptic ulcer with or without Helicobacter pylori infection: a systematic review and network Meta-analysis","volume":"17","author":"Ouyang","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"e19357","DOI":"10.1097\/MD.0000000000019357","article-title":"Vonoprazan vs proton pump inhibitors in treating post-endoscopic submucosal dissection ulcers and preventing bleeding: a meta-analysis of randomized controlled trials and observational studies","volume":"99","author":"Martin","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.12659\/MSM.911886","article-title":"Comparison of the use of vonoprazan and proton pump inhibitors for the treatment of peptic ulcers resulting from endoscopic submucosal dissection: a systematic review and meta-analysis","volume":"25","author":"He","year":"2019","journal-title":"Med Sci Monit"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12876-024-03198-8","article-title":"Comparison of vonoprazan and proton pump inhibitors for the treatment of gastric endoscopic submucosal dissection-induced ulcer: an updated systematic review and meta-analysis","volume":"24","author":"Chen","year":"2024","journal-title":"BMC Gastroenterol"},{"key":"ref63","year":"2021"}],"container-title":["Frontiers in Nutrition"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2024.1436993\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T15:27:10Z","timestamp":1725550030000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2024.1436993\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,5]]},"references-count":63,"alternative-id":["10.3389\/fnut.2024.1436993"],"URL":"https:\/\/doi.org\/10.3389\/fnut.2024.1436993","relation":{},"ISSN":["2296-861X"],"issn-type":[{"value":"2296-861X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,5]]},"article-number":"1436993"}}